Helping clients meet their business challenges begins with an in-depth understanding of the industries in which they work. That’s why KPMG LLP established its industry-driven structure. In fact, KPMG LLP was the first of the Big Four firms to organize itself along the same industry lines as clients.

How We Work

We bring together passionate problem-solvers, innovative technologies, and full-service capabilities to create opportunity with every insight.

Learn more

Careers & Culture

What is culture? Culture is how we do things around here. It is the combination of a predominant mindset, actions (both big and small) that we all commit to every day, and the underlying processes, programs and systems supporting how work gets done.

Learn more

KPMG in Precision Medicine

KPMG supports clients across the worldwide precision medicine ecosystem in their strategic and operational goals, helping them drive top- and bottom-line growth in their businesses. Our ‘one firm’ approach, proprietary data, thought leadership, and deep sector expertise means we can bring unique insights and experience to solve our clients’ most complex business issues.

Precision Medicine is a rapidly evolving market, with technologies such as liquid biopsy, gene therapy, and spatial omic imaging set to change treatment paradigms and improve clinical outcomes for patients. However, this complexity offers unique challenges for life science organizations, as they grapple with the impact across their business - from R&D to supply chain, through to commercialization.

The KPMG Precision Medicine practice is a leader in innovation across all therapeutic areas, in markets around the world. Our comprehensive offerings range from strategic front-end ideation and planning, to commercial, financial, and operational due diligence, and continuing through integration and separation. Our approach is fueled by proprietary clinical and laboratory data which is unparalleled in the market. See below for more examples of the transformative work we are doing in strategy, deals and operations for all stakeholders in the Precision Medicine ecosystem.

What we do: Strategy, deals and operations

Explore more videos

Navigating innovation in the new normal

Precision Medicine

The field of precision medicine has changed for everyone.

Download PDF

Who we work with

Our industry depth, decades long experience, and local market knowledge means we deliver the critical insights needed to inform the key strategic decisions our clients must take to be market leaders in Precision Medicine.

Hospitals, Healthcare Systems, and Labs

Biopharma Companies

Diagnostic & Life Science Tools Companies

Private Investors

KPMG proprietary Precision Medicine database

Survey data from pathologists and oncologists

Precision Medicine Insight Database
Analytics & use cases

KPMG’s proprietary Precision Medicine Insight database is used to supplement all our strategy and deals work in this sector worldwide. Survey data is collected annually from molecular pathologists, anatomical pathologists and oncologists in 13 markets, across 4 tumor types: - Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Colorectal Cancer, and Non-Hodgkins Lymphoma (NHL). This data is supplemented by 1-1 qualitative conversations to gain additional insights into how key stakeholders view evolution of the testing landscape and overall Precision Medicine market in the next 5 years.

To understand more about our Precision Medicine Insight database, please contact us.

Example Oncologist Question

Oncologists expect the rapid uptake of liquid biopsy for patient monitoring in the next 5 years if technical hurdles are overcome and sufficient evidence is generated. Data from 4 of the 13 countries below. To understand more about trends across all markets, please contact us
Number of patients per 100 new cancer patients treated where liquid biopsy tests are ordered for monitoring / progression purposes, today and in 5 years (n = 548)1 Notes: (1) Data may disproportionately represent HCPs at larger AMCs and national cancer centers with better funding/access and treat patients of higher socioeconomic status.

Example Pathologist Question

Pathologists expect the use of IVD NGS kits to grow rapidly, but this is not a uniform trend across all markets. Data from 4 of the 13 countries below. To understand more about trends across all markets, please contact us.
Number of NGS tests performed using IVD designated kits per 100 NGS tests performed on clinical cancer samples, today and in 5 years (n = 334)

Explore Precision Medicine insights

Thank you!

Thank you for contacting KPMG. We will respond to you as soon as possible.

Contact KPMG

Use this form to submit general inquiries to KPMG. We will respond to you as soon as possible.

By submitting, you agree that KPMG LLP may process any personal information you provide pursuant to KPMG LLP's Privacy Statement.

An error occurred. Please contact customer support.

Job seekers

Visit our careers section or search our jobs database.

Submit RFP

Use the RFP submission form to detail the services KPMG can help assist you with.

Office locations

International hotline

You can confidentially report concerns to the KPMG International hotline

Press contacts

Do you need to speak with our Press Office? Here's how to get in touch.